Statin use by men receiving androgen deprivation therapy for advanced PCa was associated with decreased risk of overall and cancer-specific mortality.
Researchers found no significant difference in 30-day postoperative complications between patients who received neoadjuvant chemotherapy and those who did not.
In a recently published study, external beam radiation therapy for localized prostate cancer was associated with a 35% increased risk of bladder cancer compared with radical prostatectomy.
Stereotactic body radiation therapy achieves good local control of metastases in patients with recurrent prostate cancer following primary treatment.
Widowed patients with bladder urothelial carcinoma have the worst 5-year cancer-specific survival rates among unmarried patients.
In a phase 3 trial, Prostvac-V/F did not significantly prolong overall survival among men with asymptomatic or minimally symptomatic mCRPC.
Abiraterone plus prednisone was associated with significantly greater PSA progression-free survival among patients who are black compared with white patients.
Salvage therapy guided by 68Ga-PSMA11 PET/CT resulted in high biochemical response rates.